Bellerophon Therapeutics announced on July 27 that top-line results from a clinical trial found its investigational cardiac implantable device did not improve outcomes compared with placebo.
CEO Jonathan Peacock said in a news release that the company was “clearly disappointed” with the results of the randomized, double-blind, placebo-controlled study. The company said there were no statistically significant treatment differences or adverse event rates in patients treated with its Bioabsorbable Cardiac Matrix (BCM) or placebo.
The BCM is being tested to prevent heart failure after people have an acute MI. Bellerophon said it would present detailed results of the trial, dubbed PRESERVATION I, on Sept. 1 at the European Society of Cardiology meeting in London.